Estriol facial products compared: cream, serum and disclosed placement

Estriol's inclusion makes hormone identity relevant even when the intended outcome is cosmetic appearance. FDA states that no estriol-containing drugs are FDA-approved and that it has not established them as safer forms of estrogen. That is a boundary for every offer here, not a reason to award approval points to one brand. FDA explanation.

The estrogen-identity guide distinguishes facial skincare from treatment of hot flashes or vaginal symptoms. A facial offer is not evidence of an approved substitute for those treatments. Claims about low potency, local action or botanical origins do not independently settle systemic exposure or individual risk.

CoreAge identifies estriol 0.3%, vitamin C 5% and hydrolyzed hyaluronic acid 0.5%. Its product page explicitly recognizes hormonal activity and possible absorption, while the offer has both estrogen warnings and language distancing the product from hormone therapy. The full base and physical supply remain unclear. CoreAge description and offer.

The Time Out review preserves that tension rather than treating facial positioning as hormone-free status. It also identifies the preparation as an advertised compounded topical, without inferring a verified cream vehicle or claiming that the three ingredients perform better together than a studied comparator.

Midi's main page advertises $149 for 90 days and 90 mL. Its express page describes three 30 mL dispensers and publishes an ingredient list. That page lists estriol 0.3%, DMAE 0.3% and hyaluronic acid 0.5%, whereas the linked product monograph lists DMAE at 3%. The differing DMAE figure remains unresolved. Main page, express record, monograph.

The Midi review also distinguishes the main page's no-visit pathway from the express FAQ's visit wording. Neither discrepancy establishes what a particular patient would receive or experience. They are concrete questions for clarification, not conclusions about clinical quality.

The serum offer is $159 for a three-month supply. Public product metadata specifies a 45-gram bottle with estriol 0.3%, two named peptides each at 0.1%, and hyaluronic acid 0.5%. These are advertised product specifications, not measurements of a dispensed bottle. The product is a serum, not M4 Face Cream Rx. Exact serum record.

The distinction is especially important because the serum page's prominent clinical-results block explicitly names the face cream. Our Alloy serum review keeps those claims attached to the product studied, instead of presenting a cream's reported outcomes as established serum results.

The 1996 estriol research abstract reports findings in 59 preclimacteric women over six months, with estradiol and estriol preparations compared. It does not identify any of the present three offers as the tested product. Its limited reported safety observations cannot settle long-term risk for a later formulation. Primary abstract.

Alloy also supplies company summaries of a cream study. Its blog describes 40 women while a skincare-page disclosure describes a 2024 study with 86 participants; the relationship between those figures is not resolved in the reviewed summaries. We do not combine them or construct a cross-brand effect ranking. Study summary and collection disclosure.

The older estriol paper was available here as a primary abstract, while the M4 accounts are provider summaries. Those access levels offer different amounts of methodological detail. Neither source type gives this publication a basis to predict an individual facial product’s benefit or long-term hormonal safety.

CoreAge's annual total is $576 alongside $48 monthly wording. Shorter plans show six months at $330/$54.99 monthly, three at $189/$62.99 and one at $75/$74.99. Midi's named offer is $149 per 90-day supply, while Alloy advertises $159 per three-month serum bottle. These are source-specific prices and units, not equal-treatment amounts. CoreAge plans, Midi offer, Alloy offer.

Different vehicle records and package information prevent a simple cost-per-result conclusion. No billing, shipping, prescription approval or personal consumption was tested. A longer supply description is not a direction to continue treatment for that period.

The unanswered details include the actual dispensed label, relevant medical history, the intended outcome and the evidence for that exact preparation. FDA's compounding explanation states the absence of premarket approval verification; a provider review cannot be represented as that missing product approval. Compounding context.

Our hydration-and-firmness guide and photograph guide distinguish visible or reported changes from broader clinical conclusions. The offers can be described precisely without declaring a winner. A commercial first position, a reported study percentage and a personal safety assessment remain different kinds of information.